ECSP23036210A - Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activación de plaquetas - Google Patents

Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activación de plaquetas

Info

Publication number
ECSP23036210A
ECSP23036210A ECSENADI202336210A ECDI202336210A ECSP23036210A EC SP23036210 A ECSP23036210 A EC SP23036210A EC SENADI202336210 A ECSENADI202336210 A EC SENADI202336210A EC DI202336210 A ECDI202336210 A EC DI202336210A EC SP23036210 A ECSP23036210 A EC SP23036210A
Authority
EC
Ecuador
Prior art keywords
cyclopentathiophen
antagonists
factor receptor
platelet activation
carboxamide derivatives
Prior art date
Application number
ECSENADI202336210A
Other languages
English (en)
Inventor
Ferenc Kontes
Matthias Eckhardt
Marina Willwacher
Christofer Tautermann
Juergen Prestle
Dieter Wiedenmayer
Leo Thomas
Original Assignee
Boehringer Ingelheim Int Gmbh [De/De]
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int Gmbh [De/De] filed Critical Boehringer Ingelheim Int Gmbh [De/De]
Publication of ECSP23036210A publication Critical patent/ECSP23036210A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Ciclopentatiofen carboxamidas de la Fórmula (I.0), en donde R1, R2, R3, R4 y n son como se definen en la descripción y las reivindicaciones, y las sales de este aceptables desde el punto de vista farmacéutico pueden usarse en métodos para el tratamiento de enfermedades que pueden estar influenciadas por antagonizar la actividad mediada por el receptor del factor de activación de plaquetas.
ECSENADI202336210A 2020-11-16 2023-05-17 Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activación de plaquetas ECSP23036210A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20207719 2020-11-16

Publications (1)

Publication Number Publication Date
ECSP23036210A true ECSP23036210A (es) 2023-06-30

Family

ID=73543025

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202336210A ECSP23036210A (es) 2020-11-16 2023-05-17 Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activación de plaquetas

Country Status (19)

Country Link
US (2) US11766443B2 (es)
EP (1) EP4244229A1 (es)
JP (2) JP7465368B2 (es)
KR (1) KR20230109692A (es)
CN (2) CN117624188A (es)
AR (1) AR124070A1 (es)
AU (1) AU2021379248A1 (es)
CA (1) CA3200710A1 (es)
CL (2) CL2023001361A1 (es)
CO (1) CO2023005894A2 (es)
CR (1) CR20230211A (es)
DO (1) DOP2023000090A (es)
EC (1) ECSP23036210A (es)
IL (1) IL302769A (es)
JO (1) JOP20230107A1 (es)
MX (1) MX2023005678A (es)
PE (1) PE20231855A1 (es)
SA (1) SA523440809B1 (es)
WO (1) WO2022101377A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119842821A (zh) * 2025-01-06 2025-04-18 华中科技大学 稳定表达血小板活化因子受体的细胞株、构建方法及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3502392A1 (de) 1985-01-25 1986-07-31 Boehringer Ingelheim KG, 6507 Ingelheim Neue thieno-triazolo-1,4-diazepino-2- carbonsaeureamide, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen
JPS62181282A (ja) * 1986-01-21 1987-08-08 ベ−リンガ−　インゲルハイム　コマンデイツト　ゲゼルシヤフト チエノ−１，４−ジアゼピン
PH30676A (en) 1986-07-22 1997-09-16 Boehringer Ingelhein Kg Hetrazepine compounds which have useful pharmaceutical utility
MC1999A1 (fr) * 1987-12-18 1990-01-26 Hoffmann La Roche Composes tricycliques
US4959361A (en) * 1987-12-18 1990-09-25 Hoffmann-La Roche Inc. Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists
DE3909012A1 (de) 1989-03-18 1990-09-20 Boehringer Ingelheim Kg Verbessertes verfahren zur herstellung von enantiomerenreinen hetrazepinen
DE4010528A1 (de) 1990-04-02 1991-10-17 Boehringer Ingelheim Kg Praeparativ chromatographisches trennverfahren zur herstellung enantiomerenreiner hetrazepine
DE4132763A1 (de) 1991-10-02 1993-04-08 Boehringer Ingelheim Kg Verbessertes verfahren zur herstellung von enantiomerenreinen saeureamiden hetrazepinoider struktur
FR2779652B1 (fr) 1998-06-15 2001-06-08 Sod Conseils Rech Applic Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique
US20050032713A1 (en) * 2002-03-27 2005-02-10 Wurtman Richard J. Platelet-activating factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents
CA2670031A1 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors

Also Published As

Publication number Publication date
DOP2023000090A (es) 2023-06-15
JP7810743B2 (ja) 2026-02-03
JP2024099528A (ja) 2024-07-25
US11766443B2 (en) 2023-09-26
US20220160725A1 (en) 2022-05-26
AR124070A1 (es) 2023-02-08
JP2023521200A (ja) 2023-05-23
PE20231855A1 (es) 2023-11-21
CN117624188A (zh) 2024-03-01
JOP20230107A1 (ar) 2023-05-16
EP4244229A1 (en) 2023-09-20
US20230355638A1 (en) 2023-11-09
CL2024000317A1 (es) 2024-07-12
JP7465368B2 (ja) 2024-04-10
KR20230109692A (ko) 2023-07-20
MX2023005678A (es) 2023-05-26
IL302769A (en) 2023-07-01
CA3200710A1 (en) 2022-05-19
CO2023005894A2 (es) 2023-05-29
WO2022101377A1 (en) 2022-05-19
CR20230211A (es) 2023-07-13
CL2023001361A1 (es) 2023-11-03
SA523440809B1 (ar) 2024-10-08
TW202237620A (zh) 2022-10-01
CN116745300A (zh) 2023-09-12
AU2021379248A1 (en) 2023-06-22
AU2021379248A9 (en) 2024-10-10

Similar Documents

Publication Publication Date Title
ECSP21012498A (es) COMPUESTOS DE PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET
CO2021014155A2 (es) Derivados de 1,1-dióxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2
CL2021001406A1 (es) Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso.
ECSP21034668A (es) Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento de cáncer
UY28059A1 (es) Nuevos derivados de dihidropirimido (4,5-d) pirimidona sustituida por amino. fabricacion y uso de los mismos como agentes farmaceuticos.
MX376465B (es) Compuestos de pirazolo[1,5-4]piridina sustituidos como inhibidores de la quinasa ret.
PA8504801A1 (es) Nuevos derivados de biarileter utiles como inhibidores de la recaptacion de monoaminas
UY28578A1 (es) Derivados de amida
CO5560573A2 (es) Derivados activos de amino-ftalazinona como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20210856A1 (es) Derivados sustituidos de la carboxamida dihidropirazolo pirazina
CL2019002601A1 (es) Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos.
CL2023001574A1 (es) Uso de activadores de sgc para el tratamiento de enfermedades oftalmológicas
ECSP23036210A (es) Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activación de plaquetas
CL2023001244A1 (es) Derivados de carboxamida heteroaromática como inhibidores de la calicreína plasmática
UY37972A (es) Derivados de indol macrocíclicos sustituidos con cloro
AR038483A1 (es) Derivados de quinazolinona, un proceso para su produccion, composiciones farmaceuticas y el uso de los mismos para la fabricacion de un medicamento como agonistas canabinoides
PE20221916A1 (es) Compuestos quimicos
MX2021016068A (es) Derivados de isoquinolinona como inhibidores de la proteina quinasa rock y usos del mismo.
MX2020013895A (es) Agentes inhibidores de ask1.
CL2023003117A1 (es) Compuestos agonistas de gpr35
AR049343A1 (es) Derivados tioeter, su obtencion y utilizacion de los mismos como agentes farmaceuticos
AR131509A1 (es) Inhibidores del inflamasoma nlrp3
CO2025010725A2 (es) Compuestos moduladores de receptores de dopamina d3/d2
DOP2009000145A (es) Derivados de 8-etinilxantina como antagonistas de receptores de a2a selectivos
UY27534A1 (es) Amidas de ácido antranílico y uso farmacológico de las mismas.